24.30

3.65% -0.92

Pre-market: 23.89 -0.41 -1.69%

Kailera Therapeutics Inc (KLRA)

Overview News Price History Discussions Forecast

Kailera Therapeutics Inc stock is traded at $24.30, with a volume of 890.80K. It is down -3.65% in the last 24 hours and up +0.00% over the past month. Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Previous Close:

$25.22

Open:

$25.17

24h Volume:

890.80K

Relative Volume:

19.21

Market Cap:

$3.15B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.00%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$23.65

$25.75

1-Week Range:

$23.65

$28.23

52-Week Range:

$23.65

$28.23

Kailera Therapeutics Inc Stock (KLRA) Company Profile

Name

Kailera Therapeutics Inc

Sector

Healthcare (1109)

Industry

Biotechnology (620)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

KLRA's Discussions on Twitter

Compare KLRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KLRA Kailera Therapeutics Inc	24.30	3.27B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	437.67	111.05B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	746.58	79.01B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	793.22	50.08B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	310.58	41.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.41	34.67B	5.36B	287.73M	924.18M	2.5229

Kailera Therapeutics Inc Stock (KLRA) Financials Data

There is no financial data for Kailera Therapeutics Inc (KLRA). Check out other stocks for more information.

Revenue

Net Income

Cash Flow

EPS

Kailera Therapeutics Inc Stock (KLRA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581